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Background: Interaction between advanced glycation end product (AGE) and receptor for AGE (RAGE) triggers the escalation 
of inflammatory cytokine expressions. High-sensitivity C-reactive protein (hsCRP), an important inflammatory marker, has 
been reported to be modulated by soluble RAGE (sRAGE). However, the relationship between hsCRP and sRAGE in diabetes 
was not clearly described. Therefore present study was conducted to determine the relationship between sRAGE with 
hsCRP in men with central obese diabetic and non-diabetic. 
Materials and Methods: Adult men aged 25-60 years with central obese diabetes and non-diabetes, were recruited. Patient’s 
profiles were collected before the physical and blood examination. Physical examinations were conducted by measuring 
waist/abdomen, blood pressure, height, and weight. The routine blood test was performed to obtain concentrations of 
fasting blood glucose, HbA1c, hsCRP and sRAGE level.
Results: Fifty-seven subjects with central obese and waist size ≥90 cm were selected. It was found that hsCRP values were 
significantly different (p=0.000) in HbA1c <6.5% dan HbA1c ≥6.5% groups. There was an inverse relationship between hsCRP 
and sRAGE levels for both in HbA1c <6.5% (r=-0.073) and HbA1c≥6.5% (r=-0.022) groups. In HbA1c ≥6.5% group, sRAGE 
showed strong positive correlation with 1 mg/dL ≤ hsCRP <3 mg/dL group (r>0.5).
Conclusion: In the early stages of diabetes with hsCRP <1 mg/dL, the protective function was demonstrated with greater 
sRAGE levels. However, in further phase with 3 ≤ hsCRP < 10 mg/dL, the level of sRAGE was low, which is assumed to 
be associated with complications. Hence, sRAGE could be suggested as a complementary marker for hsCRP to evaluate 
diabetic men with central obesity.
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Introduction
The prevalence of obesity in adult Indonesians increased 
rapidly from 1993 to 2007, by around 11% points (from 
20.8 to 31.2%) in men and 16% (from 32.0 to 48.8%) in 
women. In contrast, the prevalence of obesity globally rose 
by about 8.1% in men and 8.2% in women from 1980 to 
2013.1 Thus, the prevalence of obesity in Indonesian women 
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nearly doubled compared with that of women globally. The 
occurrence of obesity is proposed caused by both physical 
inactivity and consumption of food. In fact, the increase in 
obesity has occurred among all socioeconomic groups and 
cannot be explained genetically.
 Accumulation of fat in obese individuals, particularly 
in visceral obesity is associated with many chronic metabolic 
disorders characterized by abnormal cytokine production, 
increased acute phase reactants, mediators, and activation 
of inflammatory signaling pathways.2 Some recent data 
show the plasma concentration of inflammatory mediators, 
such as tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6) increases in insulin resistance that underlies obesity 
and type 2 diabetes, which then raises the question of the 
underlying mechanisms in both conditions.3 In addition, 
plasma level of high-sensitivity C-reactive protein (hsCRP), 
a marker of inflammation, has been reported as a simple 
predictor of metabolic syndrome.
 Under conditions of hyperglycemia in diabetes, 
endogenous non-enzymatic glycosylation on proteins and 
lipids triggers the formation of a heterogeneous product, 
called advanced glycation end-product (AGE). The bond 
between AGE and cell surface receptor for AGE (RAGE) 
produces conduction process of cellular signals that activate 
nuclear factor (NF)-κB, increase the expression of cytokines 
and adhesion molecules, and induce oxidative stress. AGE-
RAGE system plays an important role in the development 
of microvascular complications of diabetes.4 Various 
evidences collected also show that RAGE is involved in 
macrovascular diabetic complications.5
 The expression of RAGE is observed in adipocytes 
as well as immune cells, endothelial cells, and pancreatic 
β cells under certain conditions. It has been reported that 
RAGE is implicated in adipocyte hypertrophy and insulin 
resistance. RAGE-mediated regulation of adiposity and 
inflammation may attribute to type 2 diabetes and diabetic 
vascular complications.6 RAGE provides a new target 
for the treatment interventions to reduce and prevent the 
development of side effects of hyperglycemia. It is possible 
to make personalized therapy against RAGE to inhibit 
disease progression.7
 Secreted RAGE isoform, called soluble RAGE 
(sRAGE), has the ability to prevent the side effects of 
RAGE signal conduction to act as bait. sRAGE has been 
successfully used in some animal models which suffered 
vascular damage mediated by RAGE.8 Therefore, the 
present study was conducted to determine the relationship 
between sRAGE with hsCRP in men with central obese 
diabetic and non-diabetic.
Materials and methods
Subject recruitment and sample collection
Adult men aged 25-60 years with central obese diabetes and 
non-diabetes according to body mass index (BMI) of Asia 
Pacific in 2000 and hemoglobin A1C (HbA1C) results, were 
recruited in Prodia Clinical Laboratory in Solo, Indonesia. 
Diabetes Mellitus Consensus 2015 was used as the reference.
Examination and data collection
Patient’s profiles were collected before the physical and 
blood examination. Physical examinations were conducted 
by measuring waist, blood pressure, height, and weight. 
The routine blood test was performed in Prodia Clinical 
Laboratory, Jakarta and Prodia Clinical Laboratory, Solo, 
to obtain concentrations of fasting blood glucose, HbA1c, 
hsCRP and sRAGE level.
Data analysis
The data obtained were processed by SPSS for Windows 
version 16 with univariate and bivariate analysis. The 
significance level was set at 5%.
Results
General characteristics
Fifty-seven subjects with central obese and waist size ≥90 
cm were selected. The results of the physical examination 
showed the average age of the participants was 40.77±11.31 
years. The subjects were grouped based on HbA1c and 
hsCRP (Table 1).
 Data from 57 subjects showed that average of HbA1c 
was 6.1%, the average of hsCRP was 2.27 mg/dL, and the 
average of sRAGE was 889.57 pg/mL. The average of 
Table 1. General characteristics of subjects.
Parameters Limit value Total (n) %
HbA1c < 6.5% 45 78.9
HbA1c  6.5% 12 21.1
hsCRP < 1 mg/dL 14 24.6
1  hsCRP < 3 mg/dL 26 45.6
3  hsCRP < 10 mgl/dL 17 29.8
HbA1c
hsCRP 
*These data were normally distributed according to Kolmogorov-
Smirnov test in whole data and each category. 
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HbA1c <6.5% group was 5.73%, and the average of HbA1c 
≥6.5% group was 7.51%. General characteristics of the 
subject are shown in Table 2 and Table 3.
Differences between HbA1c <6.5% and  ≥6.5% groups
Independent Sample T-test was used to see the differences 
between various parameters within HbA1c <6.5% dan 
HbA1c ≥6.5% groups. It was found that hsCRP values were 
significantly different, while the value of sRAGE in both 
groups was not significantly different (Table 4).
Correlation between hsCRP and sRAGE
There was an inverse relationship between hsCRP and 
sRAGE levels for both in HbA1c <6.5% (r=-0.073) and 
HbA1c≥6.5% (r=-0.022) groups. It is assumed that the 
increase of blood glucose levels, which represented by the 
examination of blood glucose levels for 3 months (HbA1c), 
causes enhancement of hsCRP accompanied by depletion 
of sRAGE.
Correlation between hsCRP and sRAGE within 
HbA1c<6.5% and HbA1c≥6.5% group
sRAGE have weak correlation to three categories of hsCRP 
based on the average of sRAGE on hsCRP groups in non-
diabetic patients (HbA1c <6.5%). hsCRP <1 mg/dL and 
3 mg/dL ≤ hsCRP < 10 mg/dL groups had low negative 
correlation to sRAGE, only 1 mg/dL ≤ hsCRP < 3 mg/dL 
(n) Mean Median SD Min Max
HbA1c (%) 12 7.51 6.95 0.28 6.5 11.1
hsCRP (mg/dL) 12 2.46 2.09 0.18 0.69 7.19
sRAGE (pg/mL) 12 1,094.38 858.25 118.06 406.8 3,690
Table 3. General characteristics of the subject in HbA1c ≥6.5% group.
(n) Mean Median SD Min Max
HbA1c (%) 45 5.73 5.7 0.02 4.6 6.4
hsCRP (mg/dL) 45 2.23 1.78 0.23 0.3 7.8
sRAGE (pg/mL) 45 834.96 761.6 36.68 337.4 1,468
Table 2.  General characteristics of subject in HbA1c <6.5% group.
group showed positive correlation (Table 5). In HbA1c 
≥6.5% group, sRAGE showed strong positive correlation 
with 1 mg/dL ≤ hsCRP <3 mg/dL group (r>0.5), but showed 
low negative correlation in 3 mg/dL ≤ hsCRP < 10 mg/dL 
group (Table 6).
Discussion 
HsCRP is an important inflammatory marker and predictor 
of cardiovascular disease.9-11 hsCRP is synthesized mainly 
in hepatocytes as a response to inflammatory cytokines. The 
interaction between AGE and RAGE triggers escalation 
of inflammatory cytokine expressions, such as TNF-α, IL-
1, and IL-6 through NF-κB. Furthermore, recent studies 
have shown that sRAGE modulate the synthesis of hsCRP. 
Circulating sRAGE has a negative correlation with hsCRP 
in patients with type 2 diabetes mellitus.12 Similar to this 
study, in both HbA1c <6.5% and ≥6.5% groups of current 
study, there was a negative correlation between sRAGE 
and hsCRP. Previous studies have documented inverse 
correlations between sRAGE with CRP13 and low levels of 
sRAGE among persons with coronary heart disease14.
 sRAGE can serve as a ‘bait’ receptor to catch ligand 
and able to inhibit the cellular signaling. AGE is estimated to 
be a linking factor between RAGE and metabolic syndrome 
or atherosclerosis.5 Other study confirmed these allegations 
by proposing new considerations that sRAGE potentially to 
Table 4.  The differences between HbA1c<6.5% dan HbA1c≥6.5% group.
HbA1c < 6.5% HbA1c  6.5% p value
hsCRP (mg/dL) 2.23 2.46 0.000*
sRAGE (pg/mL) 834.96 1,094.38 0.09
*p<0.05: significant result
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be used as complement parameter for hsCRP. sRAGE might 
be considered “the next CRP,” due to its role in the setting 
of autoimmunity and inflammatory disease.7 Since sRAGE 
is a proteolytically cleaved form of RAGE that acts as an 
inhibitor of AGE-mediated signaling, it has been suggested 
that it could reduce the proinflammatory, prothrombotic and 
proatherosclerotic events of the activation of AGE-RAGE 
signalling.15 In line with this hypothesis, recent animal 
studies have shown that administration of sRAGE has a 
protective effect on diabetic vascular inflammation and 
atherosclerosis.16 
 On the increase of inflammatory conditions, such as 
diabetes or aging, sRAGE serum can be an inflammatory 
marker rather as bait. This is because of the evidence that 
sRAGE serum formation through proteolysis cutting is a 
part of the regulatory process and reflects the inflammation. 
In other hand, sRAGE concentration is associated with low 
prevalence of the metabolic syndrome, even with high level 
of hsCRP. These results indicated that the concentration 
of sRAGE may be a marker of inflammation in conditions 
of increased hsCRP and has a negative correlation with 
cardiovascular disease and its risk factors, such as metabolic 
syndrome. 
 In the early stages of diabetes without complications 
(HbA1c <6.5% group) with low-grade of inflammation 
(hsCRP <1 mg/dL), the protective function was 
demonstrated with greater sRAGE levels. In this case, 
sRAGE acted as a decoy of RAGE. In the phase of further 
tissue damage (in the group with HbA1c ≥6.5%), the level 
of sRAGE was found to be low with an average hsCRP level 
of 4.61 mg/dL, negative correlation with r=-0.387, which is 
assumed to be related to the occurrence of complications 
through inflammatory pathways. Probably in early diabetes, 
without complications, levels of sRAGEs are higher than 
controls without diabetes. Perhaps shedding of the increased 
expression of cell surface RAGE is a protective mechanism 
to decoy and trap the accumulating deleterious ligands, 
such as AGE, S100/calgranulins, high-mobility group 
box 1 (HMGB1) and membrane attack complex (mac)-1. 
However, in late stages of the disease when quite advanced 
tissue damage has occurred, lower levels of sRAGEs may 
be associated with complications.17 
 Apparently, sRAGE is not only a promising 
predictive biomarker, but also a potential therapeutic 
target for the treatment and prevention, which requires 
further investigation. The relationship between sRAGE 
with cardiovascular disease may be influenced by genetic 
background with some recognized genotype of RAGE.18 
RAGE polymorphisms are expected to affect the levels of 
sRAGE independently. Another thing is the limitations of 
our study due to the lack of identification in the diverse 
circulating forms of sRAGE. Therefore, since the proportion 
of diverse isoforms of sRAGE could differ among 
individuals, the identification of the isoforms is necessary 
to be pursued, so that pathophysiology of sRAGE with 
different isoform distribution in diabetic and nondiabetic 
patients could be explored.
Conclusion
In the early stages of diabetes with low-grade of 
inflammation (hsCRP <1 mg/dL) and without complications 
(HbA1c <6.5%), the protective function was demonstrated 
with greater sRAGE levels. However, in further phase 
Table 6.  Average of sRAGE on hsCRP group in HbA1c ≥6.5% population.
Category n Average of sRAGE 
(pg/dL)
Average of hsCRP 
(mg/dL)
r value
hsCRP < 1 (mg/dL) 1 934 0.69 ~
1  hsCRP < 3 (mg/dL) 8 1,222.26 1.87 0.564
3  hsCRP < 10 (mg/dL) 3 806.8 4.61 -0.387
Table 5.  Average of sRAGE on hsCRP group in HbA1c <6.5% population.
Category n Average of sRAGE 
(pg/dL)
Average of hsCRP 
(mg/dL)
r value
hsCRP < 1 (mg/dL) 13 930.25 0.573 -0.078
1  hsCRP < 3 (mg/dL) 18 770.38 1.965 0.351
3  hsCRP < 10 (mg/dL) 14 725.2 3.01 -0.13
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with high-grade of inflammation  (3 ≤ hsCRP < 10 mg/dL) 
and presumably tissue damage (HbA1c ≥6.5%), the level 
of sRAGE was found to be low, which is assumed to be 
associated with complications. Hence, sRAGE could be 
suggested as a complementary marker for hsCRP to evaluate 
diabetic men with central obesity. 
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